Robert Lorne Hopfner - 19 Dec 2025 Form 4 Insider Report for Evommune, Inc.

Reporting relationship: Director, 10%+ Owner
Issuer ticker: EVMN on NYSE
Reported as of: 19 Dec 2025
Net transaction value: +$17,350
SEC form: 4
Accepted by SEC: 22 Dec 2025, 07:07:35 UTC
Prior SEC filing: 12 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Gregory S. Moss, Attorney-in-Fact

Key filing fact

Robert Lorne Hopfner filed Form 4 for Evommune, Inc. on 22 Dec 2025.

Key facts

This page summarizes Robert Lorne Hopfner's Form 4 filing for Evommune, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 22 Dec 2025, 07:07.

Change

Previous filing in this sequence was filed on 12 Nov 2025.
Current net transaction value: +$17,350.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001551966 Primary reporting owner

Hopfner Robert Lorne

Relationship: Director, 10%+ Owner
Address: C/O EVOMMUNE, INC., 1841 PAGE MILL ROAD, SUITE 100, PALO ALTO
Signature: /s/ Gregory S. Moss, Attorney-in-Fact
Signature date: 22 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

EVMN transaction

Common Stock

Purchase

Transaction value: $17,350
Shares: +1,000
Change %: +33%
Price: $17.35
Shares after: 4,026
Date: 19 Dec 2025
Ownership: By Trust
Footnotes: F1

EVMN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,441,032
Date: 19 Dec 2025
Ownership: By NFLS Delta III Limited
Footnotes: F2

EVMN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,632,441
Date: 19 Dec 2025
Ownership: By Pivotal bioVenture Partners Fund I, L.P.
Footnotes: F3

EVMN holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 294,502
Date: 19 Dec 2025
Ownership: By Pivotal bioVenture Partners Fund II, L.P.
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

The securities are held by a family trust, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Footnote F2

Securities are directly held by NFLS Delta III Limited ("NFLS Delta"). NFLS Delta is a wholly-owned indirect subsidiaries of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by NFLS Delta are made by the members of Nan Fung Group Holdings Limited's Life Sciences Investment Committee, who are Mr. Kam Chung Leung, Mr. Vincent Sai Sing Cheung, Mr. Stephen Pui Kuen Cheung, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao, Ms. Anna Xintong Sun, Mr. Peter Bisgaard, and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Footnote F3

Securities are directly held by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal I"). Pivotal bioVenture Partners Fund I G.P., L.P., the general partner of Pivotal I, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal I are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund I G.P., L.P., who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.

Footnote F4

Securities are directly held by Pivotal bioVenture Partners Fund II, L.P. ("Pivotal II"). Pivotal bioVenture Partners Fund II G.P. Ltd,, the general partner of Pivotal II, is a wholly-owned indirect subsidiary of Nan Fung Group Holdings Limited. Investment and voting decisions with respect to the securities held by Pivotal II are made by the members of the Investment Committee of Pivotal bioVenture Partners Fund II G.P. Ltd, who are Mr. Vincent Sai Sing Cheung, Mr. Peter Bisgaard and the Reporting Person. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his proportionate pecuniary interest therein.